Apollomics, Inc. (NASDAQ:APLMW – Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 43,253 shares, a growth of 64.2% from the July 15th total of 26,338 shares. Based on an average daily volume of 32,613 shares, the short-interest ratio is currently 1.3 days.
Apollomics Stock Down 1.2%
APLMW traded down $0.00 during mid-day trading on Wednesday, reaching $0.02. The stock had a trading volume of 3,674 shares, compared to its average volume of 61,342. The firm’s fifty day simple moving average is $0.02 and its two-hundred day simple moving average is $0.01. Apollomics has a 52 week low of $0.00 and a 52 week high of $0.23.
About Apollomics
Apollomics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and potential commercialization of novel oncology therapies. Since its founding, the company has concentrated on creating targeted and immuno-oncology candidates designed to address unmet needs in solid tumors. Apollomics maintains headquarters in the United States with key research operations in China, leveraging a dual-site strategy to accelerate global development timelines.
The company’s pipeline encompasses a range of therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates and bispecific constructs.
See Also
- Five stocks we like better than Apollomics
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
- Tesla’s Cybercab Launch Could Reshape Margins for Uber and Lyft
- Pony AI Stock Gains Traction as Robotaxi Fleet Expands Globally
- Amazon Plugs $18B Into the Southern Power Grid
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
